This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): UCART19
Description: UCART19 is an engineered T-cell product designed with a chimeric antigen receptor (CAR) against CD19. The Cellectis technology enables the use of non-patient-derived (allogeneic) T-cells, making UCART19 an off-the-shelf therapy.
Servier and Cellectis
In February 2014, Cellectis announced that it has signed a strategic collaboration agreement with Servier to develop and commercialize novel product candidates targeting leukemia and solid tumors. The partnership covers the development and potentially the commercialization of Cellectis lead product candidate, UCART19. Engineered allogeneic CD19 T-cells currently stand out as a real therapeutic innovation for treating various types of leukemias and lymphomas. The agreement also included research, development, and potentially the commercialization of five other product candidates targeting solid tumors.
Cellectis will be responsible for the R&D of certain product candidates through the end of Phase I. Servier may exercise an exclusive worldwide option for a license on each product candidate developed under the agreement. Upon exercising each option, Servier will be responsible for taking over clinical development, registration and...See full deal structure in Biomedtracker
Partners: Les Laboratoires Servier Cellectis SA
Additional information available to subscribers only: